Sanofi India (formerly known as Aventis Pharma) has launch of AllStar, its first indigenously manufactured re-usable insulin pen. Developed especially for Indian patients by Sanofi’s Medical Device Development team at Frankfurt, AllStar, is indicated for use of insulinized patients using Sanofi’s insulin portfolio. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the-art, unparalleled 10-in-1 features.
AllStar is custom-made for patients in India. It helps improve both insulin initiation and compliance and brings ease and reassurance to the lives of Indian patients, giving them the convenience of international standards at an affordable price. Further, the launch of AllStar is a significant milestone in Sanofi India’s diabetes growth story, and also underlines the Sanofi Group’s focus on diabetes, emerging markets and its regionalized approach to finding solutions that are adapted to local needs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.20 |
| Dr. Reddys Lab | 1209.85 |
| Cipla | 1224.00 |
| Zydus Lifesciences | 924.65 |
| Lupin | 2288.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: